Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009)

Market Cap	13.01B
Revenue (ttm)	2.88B
Net Income (ttm)	867.01M
Shares Out	1.67B
EPS (ttm)	0.52
PE Ratio	14.97
Forward PE	12.35
Dividend	0.25 (3.21%)
Ex-Dividend Date	May 27, 2024

Volume	6,596,576
Open	7.87
Previous Close	7.78
Day's Range	7.73 - 7.89
52-Week Range	7.56 - 11.77
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Anhui Anke Biotechnology (Group)

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,986
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2023, Anhui Anke Biotechnology (Group)'s revenue was 2.87 billion, an increase of 22.94% compared to the previous year's 2.33 billion. Earnings were 847.23 million, an increase of 20.47%.